Analysing the reasons for rejection of neurosurgery intervention in patients with Parkinson’s disease referred to an extrapyramidal movement disorders clinic

Cover Page


Cite item

Full Text

Abstract

We present findings of a 10-year retrospective study, analysing the reasons for rejection of neurosurgical intervention (deep brain stimulation or DBS) in patients with Parkinson’s disease, who were referred to an extrapyramidal movement disorders clinic and then to a neurosurgery centre. It was found that after screening, 78.6% of patients referred as candidates for neurosurgical treatment to an extrapyramidal movement disorders clinic were rejected, while 21.4% of patients were referred to a neurosurgery centre, where 12% underwent surgery. The main reasons for rejecting potential DBS candidates were: “early referral”, “inadequate pharmacotherapy”, “levodopa-resistant symptoms”, “atypical/secondary Parkinsonism”, “cognitive reasons”, “psychological reasons”, “comorbidity”, “abnormal MRI”, “poor response to levodopa medication” and “declined surgery”. Furthermore, the number of self-referrals decreased, the number of patients referred by neurologists increased, the number of rejections of ‘unsuitable’ DBS candidates decreased, and the number of ‘suitable’ candidates referred to the extrapyramidal centre increased during the time period of 10 years. In addition, the number of patients who were referred to the neurosurgery centre and underwent surgery there increased, which suggests greater awareness of the selection criteria among doctors, as well increased knowledge and experience among neurologists in both primary healthcare and specialized centres.

About the authors

Ekaterina V. Bril’

Russian Medical Academy of Continuing Postgraduate Education; N.N. Burdenko National Medical Research Center of Neurosurgery

Author for correspondence.
Email: e.brill@inbox.ru
ORCID iD: 0000-0002-6524-4490

Cand. Sci. (Med.), Assoc. Prof., Department of neurology; Head

Russian Federation, Moscow; 123098, Russia, Moscow, Marshala Novikova str., 23

Аleksey A. Tomskiy

N.N. Burdenko National Medical Research Center of Neurosurgery

Email: e.brill@inbox.ru
ORCID iD: 0000-0002-2120-0146

Cand. Sci. (Med.), Head, Group of functional neurosurgery

Russian Federation, Moscow

Anna A. Poddubskaya

N.N. Burdenko National Medical Research Center of Neurosurgery

Email: e.brill@inbox.ru
ORCID iD: 0000-0002-5776-3442

neuropsychologist, neurologist, Group of functional neurosurgery

Russian Federation, Moscow

Anna A. Gamaleya

N.N. Burdenko National Medical Research Center of Neurosurgery

Email: e.brill@inbox.ru
ORCID iD: 0000-0002-6412-8148

neurologist, Group of functional neurosurgery

Russian Federation, Moscow

Natalya V. Fedorova

Russian Medical Academy of Continuing Postgraduate Education

Email: e.brill@inbox.ru
ORCID iD: 0000-0003-2168-2138

D. Sci. (Med.), Prof., Department of neurology

Russian Federation, Moscow

References

  1. Okun M.S., Tagliati M., Pourfar M. et al. Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers. Arch Neurol. 2005;62(8):1250–1255. doi: 10.1001/archneur.62.8.noc40425. PMID: 15956104.
  2. Okun M.S., Fernandez H.H., Pedraza O. et al. Development and initial vali-dation of a screening tool for Parkinson disease surgical candidates. Neurology. 2004;63(1):161–163. doi: 10.1212/01.wnl.0000133122.14824.25. PMID: 15249630.
  3. Morgante L., Morgante F., Moro E. et al. How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism Relat Disord. 2007;13:528–531. doi: 10.1016/j.parkreldis.2006.12.013. PMID: 17347021
  4. Pal G.D., Persinger V., Bernard B. et al. The Core Assessment Program for Surgical Interventional Therapies in Parkinson’s Disease (CAPSIT-PD): tolerability of preoperative neuropsychological testing for deep brain stimulation in Parkinson’s disease. Mov Disord Clin Pract. 2015;2(4):379–383. doi: 10.1002/mdc3.12213. PMID: 30363547.
  5. Defer G.L., Widner H., Marié R.M. et al. Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD). Mov Disord. 1999;14:572–584. doi: 10.1002/1531-8257(199907)14:4<572::aid-mds1005>3.0.co;2-c. PMID: 10435493.
  6. Okun M.S., Rodriguez R.L., Mikos A. et al. Deep brain stimulation and the role of the neuropsychologist. Clin Neuropsychol. 2007;21:162–189. doi: 10.1080/13825580601025940. PMID: 17366283.
  7. Moro E., Allert N., Eleopra R. et al. A decision tool to support appropriate referral for deep brain stimulation in Parkinson’s disease. J Neurol. 2009;256(1):83–88. doi: 10.1007/s00415-009-0069-1. PMID: 19221846.
  8. Willis A.W., Schootman M., Kung N. et al. Disparities in deep brain stimu-lation surgery among insured elders with Parkinson disease. Neurology. 2014; 82(2):163–171. doi: 10.1212/WNL.0000000000000974. PMID: 25349276.
  9. Hassan A., Wu S.S., Schmidt P. et al. What are the issues facing Parkinson’s disease patients at ten years of disease and beyond? Data from the NPF-QII study. Parkinsonism Relat Disord. 2012;18(Suppl 3):S10–S14. doi: 10.1016/j.parkreldis.2012.06.014. PMID: 22776044.
  10. Lhommée E., Wojtecki L., Czernecki V. et al. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson’s disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurol. 2018;17(3):223–231. doi: 10.1016/S1474-4422(18)30035-8. PMID: 29452685.
  11. Hesham A., Mehanna R., Machado A. et al. Comprehensive, multidisciplinary deep brain stimulation screening for Parkinson patients: no room for “short cuts”. Mov Disord Clin Pract. 2014;1(4):336–341. doi: 10.1002/mdc3.12090. PMID: 30363983.
  12. Schuepbach W.M., Rau J., Knudsen K. et al. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med. 2013;368(7):610–622. doi: 10.1056/NEJMoa1205158. PMID: 23406026.
  13. Tomskiy A.A., Bril’ E.V., Gamaleya A.A. Functional neurosurgery in Parkinson’s disease in Russia. Annals of clinical and experimental neurology. 2019;13(4):10–15. doi: 10.25692/ACEN.2019.4.2. (In Russ.)
  14. Dafsari H.S., Reker P., Stalinski L. et al. Quality of life outcome after subthalamic stimulation in Parkinson’s disease depends on age. Mov Disord. 2018;33(1):99–107. doi: 10.1002/mds.27222. PMID: 29150860.
  15. Romann A.J., Dornelles S., Maineri N.L. et al. Cognitive assessment instruments in Parkinson’s disease patients undergoing deep brain stimulation. Dement Neuropsychol. 2012;6(1):2–11. doi: 10.1590/S1980-57642012DN06010002. PMID: 29213766.
  16. Barbosa E.N.B.E., Charchat-Fichman H. Systematic review of neuropsychological instruments used in subthalamic nucleus deep brain stimulation in Parkinson’s disease patients. Dement Neuropsychol. 2019;13(2):162–171. doi: 10.1590/1980-57642018dn13-020004. PMID: 31285790.
  17. Fengler S., Kessler J., Timmermann L. et al. Screening for cognitive impairment in Parkinson’s disease: improving the diagnostic utility of the MoCA through subtest weighting. PloS One. 2016;11(7):e0159318. doi: 10.1371/journal.pone.0159318. PMID: 27437705.
  18. Nazem S., Siderowf A.D., Duda J.E. et al. Montreal cognitive assessment performance in patients with Parkinson’s disease with “normal” global cognition according to mini-mental state examination score. J Am Geriatr Soc. 2009;57(2):304–308. doi: 10.1111/j.1532-5415.2008.02096.x. PMID: 19170786.
  19. Levin O.S. [Algorithms for the diagnosis and treatment of dementia]. Мoscow, 2014. 192 p. (In Russ.)
  20. Hoops S., Nazem S., Siderowf A.D. et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009;73(21):1738–1745. DOI: 10. 1212/WNL.0b013e3181c34b47. PMID: 19933974.
  21. Rothlind J.C., York M.K., Carlson K. et al. Neuropsychological changes following deep brain stimulation surgery for Parkinson’s disease: comparisons of treatment at pallidal and subthalamic targets versus best medical therapy. J Neurol Neurosurg Psychiatry. 2015;86(6):622–629. doi: 10.1136/jnnp-2014-308119. PMID: 25185211.
  22. Rughani A., Schwalb J.M., Sidiropoulos C. et al. Congress of Neurological Surgeons systematic review and evidence-based guideline on subthalamic nucleus and globus pallidus internus deep brain stimulation for the treatment of patients with Parkinson’s disease: executive summary. Neurosurgery. 2018;82(6):753–756. doi: 10.1093/neuros/nyy037. PMID: 29538685.
  23. Smeding H.M., Speelman J.D., Koning-Haanstra M. et al. Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. Neurology. 2006;66(12):1830–1836. doi: 10.1212/01.wnl.0000234881.77830.66. PMID: 16801645.
  24. Funkiewiez A., Ardouin C., Caputo E. et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75(6):834–839. doi: 10.1136/jnnp.2002.009803. PMID: 15145995.
  25. Dubois B., Slachevsky A., Litvan I. et al. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55(11):1621–1626. doi: 10.1212/wnl.55.11.1621. PMID: 11113214.
  26. Chou K.L., Lenhart A., Koeppe R.A. et al. Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates. Parkinsonism Relat Disord. 2014;20(10):1076–1080. doi: 10.1016/j.parkreldis.2014.07.008. PMID: 25085750.
  27. Wyman-Chick K.A., Martin P.K., Barrett M.J. et al. Diagnostic accuracy and confidence in the clinical detection of cognitive impairment in early-stage Parkinson disease. J Geriatr Psychiatry Neurol, 2017;30(3):178–183. doi: 10.1177/0891988717701001. PMID: 28351200.
  28. Mondolo F., Jahanshahi M., Granà A. et al. The validity of the hospital anxi-ety and depression scale and the geriatric depression scale in Parkinson’s disease. Behav. Neurol. 2006;17(2):109–115. doi: 10.1155/2006/136945. PMID: 16873922.
  29. Leentjens A.F.G., Lousberg R., Verhey F.R.J. The psychometric properties of the hospital anxiety and depression scale in patients with Parkinson’s disease. Acta Neuropsychiatrica. 2001;13(4):83–85.
  30. Accolla E.A., Pollo C. Mood effects after deep brain stimulation for Parkinson’s disease: an update. Front Neurol. 2019;10:617. doi: 10.3389/fneur.2019.00617. PMID: 31258509.
  31. Omarova S.M., Fedorova N.V., Tomskiy A.A. et al. Syndrome dopamine dysregulation and deep brain stimulation of the subthalamic nucleus in Parkinson’s disease. Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova. 2017;117(12):27–32. doi: 10.17116/jnevro201711712127-32. (In Russ.)
  32. Cummings J.L., Mega M., Gray K. et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. J Neurol. 1994;44(12):2308–2314. doi: 10.1212/wnl.44.12.2308. PMID: 7991117.
  33. Gilman S., Low P.A., Quinn N. et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163(1):94–98. doi: 10.1016/s0022-510x(98)00304-9. PMID: 10223419.
  34. Thavanesan N., Gillies M., Farrell M. et al. Deep brain stimulation in multiple system atrophy mimicking idiopathic Parkinson’s disease. Case Rep Neurol. 2014;6(3):232–237. doi: 10.1159/000368571. PMID: 25473395.
  35. Pitz V., Malek N., Tobias E.S. et al. The levodopa response varies in patho-logically confirmed Parkinson’s disease: a systematic review. Mov Disord Clin Pract. 2020;7(2):218–222. doi: 10.1002/mdc3.12885. PMID: 32071945.
  36. Machado A.G., Deogaonkar M., Cooper S. Deep brain stimulation for movement disorders: patient selection and technical options. Clevel Clin J Med. 2012;9(Suppl S2):S19–S24. doi: 10.3949/ccjm.79.s2a.04. PMID: 22761265.
  37. Saranza G., Lang A.E. Levodopa challenge test: Indications, protocol, and guide. J Neurol. 2020. doi: 10.1007/s00415-020-09810-7. PMID: 32333167.
  38. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases.J Neurol Neurosurg Psychiatry. 1992;55(3):181–184. doi: 10.1136/jnnp.55.3.181. PMID: 1564476.
  39. Postuma R.B., Berg D., Stern M. et al. MDS clinical diagnostic criteria for Parkinson‘s disease. Mov Disord. 2015;30(12):1591–1601. doi: 10.1002/mds.26424. PMID: 26474316.
  40. Benabid A.L. Benazzouz A. Hoffmann D. et al. Long-term electrical inhibition of deep brain targets in movement disorders. Mov Disord. 1998,13(Suppl S3):119–125. doi: 10.1002/mds.870131321. PMID: 9827607.
  41. Merello M., Gerschcovich E.R., Ballesteros D., Cerquetti D. Correlation between the Movement Disorders Society Unified Parkinson’s Disease rating scale (MDS-UPDRS) and the Unified Parkinson’s Disease rating scale (UPDRS) during L-dopa acute challenge. Parkinsonism Relat Disord. 2011;17(9):705–707. doi: 10.1016/j.parkreldis.2011.07.002. PMID: 21784692.
  42. Kleiner-Fisman G., Herzog J., Fisman D.N. et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord. 2006;21(Suppl 14):S290–S304. doi: 10.1002/mds.20962. PMID: 16892449.
  43. Morishita T., Rahman M., Foote K.D. et al. DBS candidates that fall short on a levodopa challenge test: alternative and important indications. Neurologist. 2011;17(5):263–268. doi: 10.1097/NRL.0b013e31822d1069. PMID: 21881468.
  44. Katz M., Kilbane C., Rosengard J. et al. Referring patients for deep brain stimulation: an improving practice. Arch Neurol. 2011;68(8):1027–1032. doi: 10.1001/archneurol.2011.151. PMID: 21825238.
  45. Lopiano L., Rizzone M., Bergamasco B. et al. Deep brain stimulation of the subthalamic nucleus in PD: an analysis of the exclusion causes. J Neurol Sci. 2002;195(2):167–70. doi: 10.1016/s0022-510x(02)00008-4. PMID: 11897249.
  46. Ooi Y., Falowski S., Wang D. et al. Simultaneous use of neurostimulators in patients with a preexisting cardiovascular implantable electronic device. Neuromodulation. 2010;14(1):20–26. doi: 10.1111/j.1525-1403.2010.00314.x. PMID: 21992157.
  47. Capelle H., Simpson R.K.Jr., Kronenbuerger M. et al. Long-term deep brain stimulation in elderly patients with cardiac pacemakers. J Neurosurgery. 2005;102(1):53–59. doi: 10.3171/jns.2005.102.1.0053. PMID: 15658096.
  48. Ozben B., Bilge A., Yilmaz E., Adalet K. Implantation of a permanent pacemaker in a patient with severe Parkinson’s disease and a preexisting bilateral deep brain stimulator. Int Heart J. 2006;47(5):803–810. doi: 10.1536/ihj.47.803. PMID: 17106151.
  49. Ashino S., Watanabe I., Okumura Y. et al. Implantation of a pacemaker in a patient with severe Parkinson’s disease and a pre-existing bilateral deep brain stimulator. Europace. 2009;11(6):834–835. doi: 10.1093/europace/eup117. PMID: 19447809.
  50. Elliott M., Momin S., Fiddes B. et al. Pacemaker and defibrillator implantation and programming in patients with deep brain stimulation. Arrhythm Electrophysiol Rev. 2019;8(2):138–142. doi: 10.15420/aer.2018.63.2. PMID: 31114689.
  51. Dinkelbach L., Möller B., Witt K. et al. How to improve patient education on deep brain stimulation in Parkinson’s disease: the CARE Monitor study. BMC Neurol. 2017;17(1):36. doi: 10.1186/s12883-017-0820-7. PMID: 28222691.
  52. Mathers J., Rick C., Jenkinson C. et al. Patients’ experiences of deep brain stimulation for Parkinson’s disease: a qualitative systematic review and synthesis. BMJ Open. 2016;6(6):e011525. doi: 10.1136/bmjopen-2016-011525. PMID: 27338883.
  53. Wang T., Zhang Y., Pan Y. et al. Development and initial validation of the Chinese version of the Florida Surgical Questionnaire for Parkinson’s Disease. Parkinsons Dis. 2020;2020:8811435. doi: 10.1155/2020/8811435. PMID: 33381295.
  54. Wächter T., Mínguez-Castellanos A., Valldeoriola F. et al. A tool to improve pre-selection for deep brain stimulation in patients with Parkinson’s disease. J Neurol. 2011;258(4):641–646. doi: 10.1007/s00415-010-5814-y. PMID: 21088849.
  55. Khodakarami H., Farzanehfar P., Horne M. The use of data from the Parkinson’s KinetiGraph to identify potential candidates for device assisted therapies. Sensors (Basel). 2019;19(10):2241. doi: 10.3390/s19102241. PMID: 31096576.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Bril’ E.V., Tomskiy А.A., Poddubskaya A.A., Gamaleya A.A., Fedorova N.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-83204 от 12.05.2022.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies